|Ticker Symbol||Entity Name||As Of Date||Company Name||Followers||Employees on Linkedin||Link||Industry||Date Added||Date Updated||Description||Website||Specialities||Logo||HQ.Street||HQ.City||HQ.State||HQ.Country||HQ.Postal||GICS Sector||GICS Industry|
|private:steminabiomarkerdiscovery||1234326||Jun 3rd, 2019 12:00AM||Stemina Biomarker Discovery, Inc.||469||18.00||Open||Biotechnology||Jun 3rd, 2019 12:31PM||Jun 3rd, 2019 12:31PM||Stemina Biomarker Discovery is a metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. Stemina’s cell based assays arise from the strategic convergence of two cutting edge technologies: human embryonic stem (hES) cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells, in response to drugs, injury or disease. Stemina opened its state-of-the-art facilities for hES cell culture and mass spectrometry in the UW Research Park in Madison Wisconsin on November 1, 2007.||Open||Developmental Toxicity Assay, LC-MS Metabolomics, Stem Cell Culture, biomarkers, mass spectrometry, cancer stem cells, tumor stem cells, toxicology, cardio toxicity, cardiomyopathy, Autism||Open||504 South Rosa Road Suite 150||Madison||WI||US||53719||Pharmaceuticals & Biotechnology|
|private:steminabiomarkerdiscovery||1234326||Mar 13th, 2018 12:00AM||Stemina Biomarker Discovery, Inc.||438||17.00||Open||Biotechnology||Mar 12th, 2018 09:02PM||Mar 12th, 2018 09:02PM||Open||Pharmaceuticals & Biotechnology|
Save and share custom queries using a private bookmarking feature, accessible to your whole team.